Fondo Bibliografico Internacional Julio-Agosto 2005
Miscelánea.
Diffuse expression of heparan sulfate
proteoglycan and connective tissue growth factor in fibrous septa with many
mast cells relate to unresolving hepatic fibrosis of congenital hepatic fibrosis.
Ozaki S, Sato Y, Yasoshima M, Harada K, Nakanuma Y. Liver International 2005;25:817-28.
Acumulo del factor de crecimiento del tejido conectivo y de la expresión
de hepatan sulfato en la fibrosis hepática congénita.
Dual Hereditary Jaundice: Simultaneous
Occurrence of Mutations Causing Gilbert's and Dubin-Johnson Syndrome. Cebecauerova
D, Jirasek T, Budisova L, Mandys V, Volf V, Novotna Z, Subhanova I, Hrebicek
M, Elleder M, Jirsa M. Gastroenterology 2005;129:315-20.
Caso clínico.
A functional polymorphism in the IL-10
promoter influences the response after vaccination with HBsAg and hepatitis
A. Hohler T, Reuss E, Freitag CM, Schneider PM. Hepatology 2005;42:72-6.
Importancia de la variabilidad genética del promotor de la IL-10 en
la respuesta immune frente a antigenos virales.
LPS-induced tyrosine nitration of
hepatic glutamine synthetase. Gorg B, Wettstein M, Metzger S, Schliess F,
Haussinger D. Hepatology 2005;42:499.
Carta.
Primary iron overload with inappropriate
hepcidin expression in V162del ferroportin disease. Zoller H, McFarlane I,
Theurl I, Stadlmann S, Nemeth E, Oxley D, Ganz T, Halsall DJ, Cox TM, Vogel
W. Hepatology 2005;42:466-72.
La mutación de la ferroportina se asocia con aumento marcado de la
ferritina pero con poca o nula lesión hepática.
The modular microarchitecture of human
liver. Teutsch HF. Hepatology 2005;42:317-25.
Aproximación al estudio morfológico y funcional del hígado.
Cystinosis as a cause of noncirrhotic
portal hypertension. Rossi S, Herrine SK, Navarro VJ. Digestive Diseases and
Science 2005;50:1372-5.
Cistinosis como causa de hipertensión portal no cirrótica.
Pediatric gallstone disease in familial
hypobetalipoproteinemia. Lancellotti S, Zaffanello M, Di Leo E, Costa L, Lonardo
A, Tarugi P. Journal of Hepatology 2005;43:188-91.
Caso clínico.
Factors affecting the uptake of screening:
a randomised controlled non-inferiority trial comparing a genotypic and a
phenotypic strategy for screening for haemochromatosis. Patch C, Roderick
P, Rosenberg W. Journal of Hepatology 2005;43:149-55.
Cribaje fenotípico o genotípico de la hemocromatosis.
Hereditary haemochromatosis: to screen
or not to screen? Olynyk JK, Trinder D, Milward E. Journal of Hepatology 2005;43:9-10.
Editorial.
Clinical, biochemical and morphological
features of hepatocerebral syndrome with mitochondrial DNA depletion due to
deoxyguanosine kinase deficiency. Labarthe F, Dobbelaere D, Devisme L, De
Muret A, Jardel C, Taanman JW, Gottrand F, Lombes A. Journal of Hepatology
2005;43:333-41.
Hepatopatía de origen mitochondrial.
Mitochondrial hepatopathies. Chinnery
PF, DiMauro S. Journal of Hepatology 2005;43:207-9.
Editorial.
Portal-splenic-mesenteric venous thrombosis
secondary to a mutation of the prothrombin gene. Frutos Bernal MD, Fernandez
Hernandez JA, Carrasco Prats M, Soria Cogollos T, Lujan Mompean JA, Hernandez
Aguera Q, Parrilla Paricio P. Gastroenterologia y Hepatologia 2005;28:329-32.
Caso clínico.
Nodular regenerative hyperplasia,
portal vein thrombosis, and avascular hip
necrosis due to hyperhomocysteinaemia. Buchel O, Roskams T, Van Damme B, Nevens
F, Pirenne J, Fevery J. Gut 2005;54:1021-3.
Caso clínico.
The molecular basis of bilirubin encephalopathy
and toxicity: report of an EASL Single Topic Conference, Trieste, Italy. Tiribelli
C, Ostrow JD. Journal of Hepatology 2005;43:156-66.
Revisión.
Proteomics in the study of liver pathology.
Parent R, Beretta L. Journal of Hepatology 2005;43:177-83.
Revisión.
Genomic and functional characterization
of stellate cells isolated from human cirrhotic livers. Sancho-Bru P, Bataller
R, Gasull X, Colmenero J, Khurdayan V, Gual A, Nicolas JM, Arroyo V, Gines
P. Journal of Hepatology 2005;43:272-82.
Las células estrelladas aisladas de hígados cirróticos
tienen propiedades profibrogénicas y contráctiles.
A novel bacterium Achromobacter xylosoxidans
as a cause of liver abscess: three case reports. Asano K, Tada S, Matsumoto
T, Miyase S, Kamio T, Sakurai K, Iida M. Journal of Hepatology 2005;43:362-5.
Achromobacter xylosoxidans como causa de absceso hepático.
Haemobilia causing acute pancreatitis
after percutaneous liver biopsy. Nowak A, Hartleb M, Kohut M, Nowakowska-Dulawa
E, Pilch-Kowalczyk J. Journal of Hepatology 2005;43:366.
Caso clínico.
The molecular adsorbent recycling
system (MARS) and transmembrane transport of albumin-bound toxins. Evenepoel
P, Bammens B, Nevens F, Wilmer A, Vanrenterghem Y. Liver Transplantation 2005;11:853-854.
Carta.
The bile duct cell: A bully or a victim?
Selmi C, Zuin M, Gershwin ME. Liver Transplantation 2005;11:878-880.
Editorial.
Severing the Gordian knot of prevention
of cytomegalovirus in liver transplant recipients: The principle is the sword.
Singh N, Yu VL. Liver Transplantation 2005;11:891-894.
Editorial.
An unusual cause of acalculous cholecystitis
during pregnancy: hepatitis A virus. Basar O, Kisacik B, Bozdogan E, Yolcu
OF, Ertugrul I, Koklu S. Digestive Diseases and Science 2005;50:1532.
Carta.
Immunization needs of chronic liver
disease patients seen in primary care versus specialist settings. Jacobs RJ,
Meyerhoff AS, Saab S. Digestive Diseases and Science 2005;50:1525-31.
Política de vacunación en pacientes con hepatitis crónica
atendidos en centros primarios o por especialistas.
Eosinophilic cholangiopathy--a case
report. Duseja A, Nada R, Dhiman RK, Chawla YK, Kalra N, Prashad S, Karwasra
RK. Digestive Diseases and Science 2005;50:1422-5.
Caso clínico.
Controversies concerning pathophysiology
and management of acalculous biliary-type abdominal pain. Rastogi A, Slivka
A, Moser AJ, Wald A. Digestive Diseases and Science 2005;50:1391-401.
Revisión.
Inflammatory pseudotumor of the liver
revealing gynecological Corynebacterium infection. Bernard M, Marie I, Riachi
G, Goria O, Lerebours E, Francois A, Levesque H, Michel P. Scandinavian Journal
of Gastroenterology 2005;40:875-7.
Caso clínico.
Effect of hepatitis A vaccination
programs. Van Damme P, Van Herck K. JAMA 2005;294:246-8.
Editorial
Incidence of hepatitis A in Israel
following universal immunization of toddlers. Dagan R, Leventhal A, Anis E,
Slater P, Ashur Y, Shouval D. JAMA 2005;294:202-10.
Eficacia de la vacunación frente a la hepatitis A en niños menores
de 18 a 24 meses.
Incidence of hepatitis A in the United
States in the era of vaccination. Wasley A, Samandari T, Bell BP. JAMA 2005;294:194-201.
Notable disminución de la incidencia de hepatitis A en Estados Unidad
tras la vacunación rutinaria frente a este virus.
Hepatitis A virus. Ringold S, Lynm
C, Glass RM. JAMA 2005;294:270.
Educativo.
A 57-year-old man with a mass in the
liver. Tanabe KK, Blaszkowsky LS, Chung RT, Blake MA, Lauwers GY. New England
Journal of Medicine 2005;353:401-10.
Caso clínico.
Screening for haemochromatosis--producing or preventing
illness? Adams PC. Lancet 2005;366:269-71.
Comentario.
